A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

被引:0
作者
B. Milojkovic Kerklaan
S. Slater
M. Flynn
A. Greystoke
P. O. Witteveen
M. Megui-Roelvink
F. de Vos
E. Dean
L. Reyderman
L. Ottesen
M. Ranson
M. P. J. Lolkema
R. Plummer
R. Kristeleit
T. R. J. Evans
J. H. M. Schellens
机构
[1] Department of Clinical Pharmacology,The Beatson West of Scotland Cancer Centre
[2] Division of Internal Medicine,Department of Medical Oncology, Cancer Center
[3] Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital,Utrecht Institute of Pharmaceutical Sciences (UIPS)
[4] University Glasgow,undefined
[5] University College London Hospital,undefined
[6] The Christie NHS Foundation Trust / University of Manchester,undefined
[7] University Medical Centre Utrecht,undefined
[8] Eisai Inc,undefined
[9] Eisai Ltd,undefined
[10] Erasmus Medical Center Cancer Institute,undefined
[11] Erasmus Medical Center,undefined
[12] Sir Bobby Robson Cancer Trials Research Centre Newcastle,undefined
[13] Utrecht University,undefined
来源
Investigational New Drugs | 2016年 / 34卷
关键词
Integrin-α2; Aromatic sulfonamide; Maximum tolerated dose; Food effect; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction E7820 is an orally administered sulfonamide that inhibits alfa-2-integrin mRNA expression. Pre-clinically E7820 showed tumor anti-angiogenic effects in various tumor cell lines and xenograft mouse models. Human daily dosing of 100 mg QD had previously been shown to be safe and tolerable. Methods The study consisted of two parts: Part A (food effect) and Part B (determination of maximum tolerated dose (MTD) for bi-daily (BID) dosing). E7820 dosing started at 50 mg BID with planned escalation to 60, 80 and 100 mg BID every 28 days. Results Fifteen patients were enrolled in Part A and 26 in Part B. The most frequent adverse events of all grades were constipation, diarrhea, nausea, and fatigue while anemia, neutropenia, and fatigue were most frequent grade ≥3 toxicities. At dose-level 60 mg BID, two patients experienced dose-limiting toxicities (grade 3 neutropenic sepsis and grade 4 neutropenia). Therefore the recommended dose (RD) was 50 mg BID. Food had no effect on E7820 exposure. E7820 exposure following twice daily administration was dose-proportional. Expression of platelet integrin-α2 measured as a response biomarker in Part B, generally decreased by a median 7.7 % from baseline following treatment with 50 mg BID E7820. Reduction was most pronounced within 1-week post treatment. The median duration of treatment was median 54, range 20–111 days. The best overall response in any treatment group was stable disease (SD): 23.1 % in Part A (100 mg QD); at the RD 66.7 % (12 of 18 patients) and 40 % in the 60 mg BID group in Part B. Conclusions:Food had no effect on E7820 exposure. A dose of 50 mg BID was considered the MTD. Treatment with E7820 is safe and tolerable with 2/3 of patients (66.7 %) at MTD having SD as their best response.
引用
收藏
页码:329 / 337
页数:8
相关论文
共 37 条
  • [1] Rüegg C(2010)Vascular integrins: therapeutic and imaging targets of tumor angiogenesis Recent Results Cancer Res 180 83-101
  • [2] Alghisi GC(2014)Integrins: players in cancer progression and targets in cancer therapy Anticancer Drugs 25 1107-21
  • [3] Sun C-C(2004)Integrins: roles in cancer development and as treatment targets Br J Cancer 90 561-5
  • [4] Qu X-J(2011)Phase I study of E7820, an oral inhibitor of integrin α-2 expression with antiangiogenic properties, in patients with advanced malignancies Clin Cancer Res 17 193-200
  • [5] Gao Z-H(2014)Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours Invest New Drugs 32 481-488
  • [6] Jin H(2014)A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy Eur Urol 65 897-904
  • [7] Varner J(2006)Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours Br J Cancer 94 1621-6
  • [8] Mita M(2011)A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma Br J Cancer 105 346-52
  • [9] Kelly KR(2013)Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer Ann Oncol 24 90-6
  • [10] Mita A(2010)Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 2712-2718